Evidence map›Paper›PMID 26813340›Full record

Trial reportMucosal immunology2016

Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel.

D Archary, K E Seaton, J S Passmore, L Werner, A Deal, L J Dunphy, K B Arnold, N L Yates, D A Lauffenburger, P Bergin and 9 more

Erratum issuedOpen access · bronzeAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Mucosal immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 5 countries.

D Archary *Centre for the AIDS Program of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
K E Seaton *Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
J S PassmoreCentre for the AIDS Program of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
L WernerCentre for the AIDS Program of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
A DealDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
L J DunphyDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
K B ArnoldDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
N L YatesDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
D A LauffenburgerDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
P BerginImperial College, International AIDS Vaccine Initiative Core Immune Monitoring Laboratory, London, UK.
L J LiebenbergCentre for the AIDS Program of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
N SamsunderCentre for the AIDS Program of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
M W MureithiKAVI Institute of Clinical Research, School of Medicine, College of Health Sciences, University of Nairobi, Nairobi, Kenya.
M AltfeldHeinrich-Pette Institut, Leibniz Institute for Experimental Virology, University of Hamburg, Hamburg, Germany.
N GarrettCentre for the AIDS Program of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
Q Abdool KarimCentre for the AIDS Program of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
Ss Abdool KarimCentre for the AIDS Program of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
L MorrisCentre for the AIDS Program of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
G D TomarasDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
University of KwaZulu-Natal · ZADuke Medical Center · USMassachusetts Institute of Technology · USCentre for the AIDS Programme of Research in South Africa · ZAColumbia University · USInternational HIV/AIDS Alliance · GBLeibniz Institute of Virology (LIV) · DENational Health Laboratory Service · ZAUniversity of Cape Town · ZAUniversity of Nairobi · KE

Funding

LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI GEORGIA Doris TOMARAS · 2005 to 2026
$50.5M
The Viral Set Point in HIV-1 Subtype C InfectionU19AI051794 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI ABDOOL KARIM, SALIM S · 2002 to 2007
$22.5M
TUBERCULOSIS SUPPLEMENTD43TW000231 · FIC · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI ABDOOL KARIM, QUARRAISHA · 1993 to 2014
$13.1M
Evolution of glycan-reactive broadly neutralizing anti-v2 antibodies in HIV infecR01AI104387 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI MORRIS, LYNN · 2013 to 2016
$2.0M
Timing of establishment of the HIV latent reservoir in subtype C infected womenR01AI115981 · NIAID · UNIVERSITY OF CAPE TOWN · PI SWANSTROM, RONALD I, WILLIAMSON, CAROLYN · 2015 to 2019
$1.7M
CAPRISA HIV-1 neutralizing antibodies: Harnessing ontogeny for immunogen designU01AI116086 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI KWONG, PETER D, MASCOLA, JOHN R · 2015 to 2019
$874k
FIC NIH HHS D43 TW000231NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI104387NIAID NIH HHS R01 AI115981NIAID NIH HHS U01 AI116086NIAID NIH HHS U19 AI051794NIAID NIH HHS UM1 AI068618
6 · The paper itself

Abstract

The impact of topical antiretrovirals for pre-exposure prophylaxis on humoral responses following HIV infection is unknown. Using a binding antibody multiplex assay, we investigated HIV-specific IgG and IgA responses to envelope glycoproteins, p24 Gag and p66, in the genital tract (GT) and plasma following HIV acquisition in women assigned to tenofovir gel (n=24) and placebo gel (n=24) in the CAPRISA 004 microbicide trial to assess if this topical antiretroviral had an impact on mucosal and systemic antibody responses. Linear mixed effect modeling and partial least squares discriminant analysis was used to identify multivariate antibody signatures associated with tenofovir use. There were significantly higher response rates to gp120 Env (P=0.03), p24 (P=0.002), and p66 (P=0.009) in plasma and GT in women assigned to tenofovir than placebo gel at multiple time points post infection. Notably, p66 IgA titers in the GT and plasma were significantly higher in the tenofovir compared with the placebo arm (P<0.05). Plasma titers for 9 of the 10 HIV-IgG specificities predicted GT levels. Taken together, these data suggest that humoral immune responses are increased in blood and GT of individuals who acquire HIV infection in the presence of tenofovir gel.

Indexed as

Administration, TopicalAdultAnti-Retroviral AgentsFemaleFollow-Up StudiesGenitalia, FemaleHIV-1HIV AntibodiesHIV Core Protein p24HIV Envelope Protein gp120HIV InfectionsHIV Reverse TranscriptaseHumansImmunoglobulin AImmunoglobulin GTenofovirAnti-Retroviral Agentsgp120 protein, Human immunodeficiency virus 1HIV AntibodiesHIV Core Protein p24HIV Envelope Protein gp120HIV Reverse TranscriptaseImmunoglobulin AImmunoglobulin Gp24 protein, Human Immunodeficiency Virus Type 1reverse transcriptase, Human immunodeficiency virus 1TenofovirVaginal Creams, Foams, and Jellies

Identifiers

PMID26813340
PMCPMC4848129
OpenAlexW2344356826

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.